What Role Can Antibody Drug Conjugates Play in Advancing Cancer Treatment Effects?

A conversation with Dr. William Lee and Marian Alva from BOC Sciences.

Cancer treatment has long been the biggest unsolved challenge facing generations of doctors and researchers. Traditionally, chemotherapy is highly commended for its credit-worthy effects in eliminating fast-spreading tumor cells; however, its side effects can by no means be neglected—healthy cells are meanwhile also killed, unfortunately.

Considering this, Antibody Drug Conjugate (or more commonly referred to as ADC) has already been explored and tried since decades ago. It is virtually a complex molecule composed of an antibody linked to a biologically active cytotoxic payload or drug. As viewed by many scientists, it stands higher chances of more effectively combating the daunting disease cancer. But why is it so? What role does ADC play in advancing cancer treatment effects?

“Unlike the conventional treatments, which will also damage healthy tissues during dose escalation, ADC intends to target and kill exclusively the cancer cells and, thus sparing healthy cells”, explains Dr. William Lee, the leading scientist of BOC Sciences’ ADC research team. When further asked about the underlying working principles, he added, “this new technique allows armed antibodies to selectively dispatch highly potent cytotoxic to cancer cells directly while, at the same time, leaving healthy tissue unaffected”.

BOC Sciences has been involved with ADC research for nearly a decade. “Years back Mr. Jones, our founder & CEO, has seen ADC’s huge potential of revolutionizing the industry, so he decides to initiate a program dedicated to ADC research”, says the spokesperson of the company Marian Alva. “You see that’s exactly why we are here.”

After years of unremitting efforts, BOC Sciences eventually stands out through fierce competitions against its counterparts. “One of our ADC products has survived the clinical trial stage and is going to enter the market after being approved and licensed by FDA authorities”, William told the reporter. “Many more are going through the same process because we have the advantage of an extended product pipeline, which will definitely help our company earn a good place in the market.”  

Ideally an ADC shows great potential in driving up the overall therapeutic index by maximizing the anti-tumor effect, and meanwhile minimizing normal tissue exposure. “However, major obstacles still remain there to be solved. Just to give some examples, we are still facing challenges like low delivery efficiency, the heterogeneity of target antigen expression in the tumor, etc.”, says Dr. William Lee with a slightly pitiful tone. “But this doesn’t mean we are intimidated. On the contrary, we are confident one day these problems will ultimately be addressed. Nothing is impossible, isn’t it?”

When asked about the future research prospects of ADC technique, Dr. William Lee shares his insights, “In future research, we’ll focus on strategies to select the best target antigens as well as suitable cytotoxic drugs, stress the toxicity issues and design of optimized linkers, and value the discovery of bio-orthogonal conjugation chemistries.” He further expounds, “As long as the ADC efficacy is ensured, the cure for cancer is likely to be materialized in the near future. By then, more people who suffer from cancer and other diseases will be saved and cured”.

About BOC Sciences

BOC Sciences is a chemical supplier & service provider. With over a decade of years’ operation experiences in the industry, it has successfully established its fame and brand. At present BOC Sciences has reached 5 million customers in 29 countries. As always, BOC Sciences is committed to offer its customers the premium products and services with the best price ever possible. 

Media Contact
Company Name: BOC Sciences
Contact Person: Linna Green
Email: account@bocsci.com
Phone: 1-631-619-7922
Address:45-16 Ramsey Road
City: Shirley
Country: United States
Website: http://www.bocsci.com